Strong Efficacy and Safety Data Observed With Telisotuzumab Vedotin for c-Met+ NSCLC
April 16th 2021A promising objective response rate and a tolerable safety profile were observed with telisotuzumab vedotin monotherapy to treat patients with previously treated c-Met–positive advanced non–small cell lung cancer.